Circulating tumor DNA in liquid biopsy: Current diagnostic limitation  

作　　者：Shi-Cai Liu 

机构地区：[1]School of Medical Information,Wannan Medical College,Wuhu 241002,Anhui Province,China

出　　处：《World Journal of Gastroenterology》2024年第15期2175-2178,共4页世界胃肠病学杂志（英文版）

基　　金：Supported by Talent Scientific Research Start-up Foundation of Wannan Medical College,No.WYRCQD2023045.

摘　　要：With the rapid development of science and technology,cell-free DNA(cfDNA)is rapidly becoming an important biomarker for tumor diagnosis,monitoring and prognosis,and this cfDNA-based liquid biopsy technology has great potential to become an important part of precision medicine.cfDNA is the total amount of free DNA in the systemic circulation,including DNA fragments derived from tumor cells and all other somatic cells.Tumor cells release fragments of DNA into the bloodstream,and this source of cfDNA is called circulating tumor DNA(ctDNA).cfDNA detection has become a major focus in the field of tumor research in recent years,which provides a new opportunity for non-invasive diagnosis and prognosis of cancer.In this paper,we discuss the limitations of the study on the origin and dynamics analysis of ctDNA,and how to solve these problems in the future.Although the future faces major challenges,it also con-tains great potential.

关 键 词：Cell-free DNA Circulating tumor DNA Liquid biopsy Cancer Diagnosis Prognosis 

分 类 号：R735[医药卫生—肿瘤]